Study to Compare Safety and Immunogenicity of Yellow Fever Vaccine of Serum Institute of India with with STAMARIL

INTERVENTION: SII YF vaccine Stamaril CONDITION: ; Yellow Fever Yellow Fever PRIMARY OUTCOME: Geometric mean titre GMT Percentage of participants showing seroprotection Percentage seroconversion on Day 28 post‐vaccination; Seroconversion is defined as a four‐fold rise in YF NAb (PRNT50) titres from baseline SECONDARY OUTCOME: All unsolicited adverse events in all participants Immediate adverse events in all participants Post‐vaccination reactogenicity (in reactogenicity cohort) ; 1. Solicited local adverse events ; 2. Solicited systemic adverse events Serious adverse events in all participants INCLUSION CRITERIA: 1. Male or female volunteers aged = 1 to < 60 years 2. Healthy volunteers as determined by medical history and clinical examination 3. Participants willing to adhere to the protocol requirements and to provide informed consent for participants = 18 years of age. For participants < 18 years of age, parental/guardian ability and willingness to provide informed consent (as per local requirements/procedures) and additional informed assent from participants, as appropriate for participating community (i.e. participants at least 7 years of age in Kenya) 4. Intend to remain residing in study area throughout study participation 5. Female participants of childbearing potential* must have practiced adequate contraception** and agree to continue adequate contraception till Day 28 post‐vaccination. *Females can be considered not of childbearing potential only if they are pre‐menarche and less than 12 years of age, or w